WO1999036553A3 - Regulation of biological events using multimeric chimeric proteins - Google Patents

Regulation of biological events using multimeric chimeric proteins Download PDF

Info

Publication number
WO1999036553A3
WO1999036553A3 PCT/US1999/000178 US9900178W WO9936553A3 WO 1999036553 A3 WO1999036553 A3 WO 1999036553A3 US 9900178 W US9900178 W US 9900178W WO 9936553 A3 WO9936553 A3 WO 9936553A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulation
biological events
chimeric proteins
multimeric chimeric
multimeric
Prior art date
Application number
PCT/US1999/000178
Other languages
French (fr)
Other versions
WO1999036553A2 (en
Inventor
Timothy P Clackson
Michael Z Gilman
Dennis A Holt
Terence P Keenan
Leonard Rozamus
Wu Yang
Original Assignee
Ariad Gene Therapeutics Inc
Timothy P Clackson
Michael Z Gilman
Dennis A Holt
Terence P Keenan
Leonard Rozamus
Wu Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/012,097 external-priority patent/US6187757B1/en
Application filed by Ariad Gene Therapeutics Inc, Timothy P Clackson, Michael Z Gilman, Dennis A Holt, Terence P Keenan, Leonard Rozamus, Wu Yang filed Critical Ariad Gene Therapeutics Inc
Priority to JP2000540254A priority Critical patent/JP2002508971A/en
Priority to EP99902059A priority patent/EP1045915A2/en
Priority to CA002318402A priority patent/CA2318402A1/en
Priority to AU22132/99A priority patent/AU755784B2/en
Publication of WO1999036553A2 publication Critical patent/WO1999036553A2/en
Publication of WO1999036553A3 publication Critical patent/WO1999036553A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.
PCT/US1999/000178 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins WO1999036553A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000540254A JP2002508971A (en) 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins
EP99902059A EP1045915A2 (en) 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins
CA002318402A CA2318402A1 (en) 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins
AU22132/99A AU755784B2 (en) 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US7159198P 1998-01-15 1998-01-15
US60/071,591 1998-01-15
US7201698P 1998-01-21 1998-01-21
US60/072,016 1998-01-21
US7221998P 1998-01-22 1998-01-22
US09/012,097 1998-01-22
US60/072,219 1998-01-22
US09/012,097 US6187757B1 (en) 1995-06-07 1998-01-22 Regulation of biological events using novel compounds

Publications (2)

Publication Number Publication Date
WO1999036553A2 WO1999036553A2 (en) 1999-07-22
WO1999036553A3 true WO1999036553A3 (en) 1999-10-21

Family

ID=27486136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000178 WO1999036553A2 (en) 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins

Country Status (5)

Country Link
EP (1) EP1045915A2 (en)
JP (1) JP2002508971A (en)
AU (1) AU755784B2 (en)
CA (1) CA2318402A1 (en)
WO (1) WO1999036553A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426167B2 (en) 2001-06-22 2013-04-23 Roche Diagnostics Operations, Inc. Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
EP2022856B1 (en) 1994-08-20 2011-09-14 Gendaq Limited Improvements in or relating to binding proteins for recognition of DNA
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
ATE466952T1 (en) 1998-03-02 2010-05-15 Massachusetts Inst Technology POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS
AU751487B2 (en) 1998-03-17 2002-08-15 Gendaq Limited Nucleic acid binding proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
ATE264863T1 (en) * 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-EPIRAPALOGUE
DE60023936T2 (en) 1999-12-06 2006-05-24 Sangamo Biosciences Inc., Richmond METHODS OF USING RANDOMIZED ZINCFINGER PROTEIN LIBRARIES FOR IDENTIFYING GENERAL FUNCTIONS
AU2001226935B2 (en) 2000-01-24 2006-06-22 Gendaq Limited Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
DK1353941T3 (en) 2001-01-22 2013-06-17 Sangamo Biosciences Inc Modified zinc finger binding proteins
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
IL162734A0 (en) 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US20080287675A1 (en) * 2007-05-18 2008-11-20 Abbott Laboratories Cascade system
SG10201908848RA (en) 2010-03-29 2019-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US20140031418A1 (en) 2011-04-20 2014-01-30 The Trustees Of The University Of Pennsylvania Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
CN110423282B (en) 2013-02-15 2023-09-08 加利福尼亚大学董事会 Chimeric antigen receptor and methods of use thereof
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
CA2956667A1 (en) * 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
CA2985081A1 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
WO2016196655A1 (en) 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
EP3377523A4 (en) 2015-11-19 2019-06-19 The Regents of The University of California Conditionally repressible immune cell receptors and methods of use thereof
CA3007473A1 (en) * 2015-12-14 2017-06-22 Bellicum Pharmaceuticals, Inc. Dual controls for therapeutic cell activation or elimination
WO2020047527A2 (en) 2018-09-02 2020-03-05 F1 Bioventures, Llc Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
WO2018161064A1 (en) 2017-03-03 2018-09-07 F1 Oncology, Inc. Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
CA3019426A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
WO2018111834A1 (en) 2016-12-13 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
JOP20190200A1 (en) 2017-02-28 2019-08-27 Univ Pennsylvania Compositions useful in treatment of spinal muscular atrophy
JP2020510430A (en) 2017-02-28 2020-04-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Influenza vaccine based on AAV vector
FI3589730T3 (en) 2017-02-28 2024-02-22 Univ Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
AR112834A1 (en) 2017-09-26 2019-12-18 Novartis Ag RAPAMYCIN DERIVATIVES
MX2020003888A (en) 2017-10-18 2020-11-06 Regenxbio Inc Fully-human post-translationally modified antibody therapeutics.
EP3697449A1 (en) 2017-10-18 2020-08-26 REGENXBIO Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
CN111565737A (en) 2017-12-14 2020-08-21 蓝鸟生物公司 DARIC interleukin receptor
WO2019212990A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
CN112368289B (en) 2018-05-01 2024-02-20 锐新医药公司 C26-linked rapamycin analogues as MTOR inhibitors
CN113286608A (en) 2018-10-05 2021-08-20 圣安娜儿童癌症研究中心 Chimeric Antigen Receptor (CAR) groups
CN113164576A (en) 2018-10-05 2021-07-23 圣安娜儿童癌症研究中心 Chimeric Antigen Receptor (CAR) groups
EP3632460A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CN113966236A (en) 2019-04-03 2022-01-21 再生生物股份有限公司 Gene therapy for ocular conditions
EP3959323A1 (en) 2019-04-24 2022-03-02 REGENXBIO Inc. Fully-human post-translationally modified antibody therapeutics
MX2022002366A (en) 2019-08-26 2022-07-19 Regenxbio Inc Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab.
MX2022004146A (en) 2019-10-07 2022-09-19 Regenxbio Inc Adeno-associated virus vector pharmaceutical composition and methods.
AU2020397938A1 (en) * 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
WO2022060916A1 (en) 2020-09-15 2022-03-24 Regenxbio Inc. Vectorized antibodies for anti-viral therapy
EP4213890A1 (en) 2020-09-15 2023-07-26 RegenxBio Inc. Vectorized lanadelumab and administration thereof
WO2022076582A1 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Gene therapy for ocular manifestations of cln2 disease
EP4236999A1 (en) 2020-10-28 2023-09-06 RegenxBio Inc. Vectorized anti-tnf-alfa antibodies for ocular indications
WO2022094157A1 (en) 2020-10-28 2022-05-05 Regenxbio Inc. Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
WO2022094255A2 (en) 2020-10-29 2022-05-05 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
MX2023004843A (en) 2020-10-29 2023-05-10 Regenxbio Inc Vectorized tnf-alpha antagonists for ocular indications.
CN116670152A (en) 2020-12-01 2023-08-29 宾夕法尼亚州大学信托人 Novel compositions having tissue-specific targeting motifs and compositions containing the same
WO2022187289A1 (en) 2021-03-01 2022-09-09 Exuma Biotech Corp. Methods and compositions for the delivery of retroviral particles
BR112023021971A2 (en) 2021-04-23 2024-02-20 Univ Pennsylvania COMPOSITIONS WITH BRAIN-SPECIFIC DIRECTION MOTIFS AND COMPOSITIONS CONTAINING THE SAME
TW202325845A (en) 2021-10-02 2023-07-01 賓州大學委員會 Novel aav capsids and compositions containing same
WO2023147304A1 (en) 2022-01-25 2023-08-03 The Trustees Of The University Of Pennsylvania Aav capsids for improved heart transduction and detargeting of liver
WO2023168305A1 (en) 2022-03-01 2023-09-07 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
WO2023201308A1 (en) 2022-04-14 2023-10-19 Regenxbio Inc. Gene therapy for treating an ocular disease
WO2023205610A2 (en) 2022-04-18 2023-10-26 Regenxbio Inc. Hybrid aav capsids
WO2023215807A1 (en) 2022-05-03 2023-11-09 Regenxbio Inc. VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
TW202400803A (en) 2022-05-03 2024-01-01 美商銳進科斯生物股份有限公司 Vectorized anti-complement antibodies and complement agents and administration thereof
WO2024073669A1 (en) 2022-09-30 2024-04-04 Regenxbio Inc. Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1996041865A1 (en) * 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1996041865A1 (en) * 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUAN I LUENGO ET AL.: "Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domainand positioned at the FKBP12-FRAP interface", CURRENT BIOLOGY, vol. 2, 1995, pages 471 - 481, XP002045681 *
VICTOR M. RIVERA ET AL.: "A humanized system for phamacologic control of gene expression", NATURE MEDICINE, vol. 2, no. 9, September 1996 (1996-09-01), pages 1028 - 1032, XP002018162 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426167B2 (en) 2001-06-22 2013-04-23 Roche Diagnostics Operations, Inc. Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides

Also Published As

Publication number Publication date
AU755784B2 (en) 2002-12-19
AU2213299A (en) 1999-08-02
CA2318402A1 (en) 1999-07-22
JP2002508971A (en) 2002-03-26
WO1999036553A2 (en) 1999-07-22
EP1045915A2 (en) 2000-10-25

Similar Documents

Publication Publication Date Title
WO1999036553A3 (en) Regulation of biological events using multimeric chimeric proteins
IL206293A0 (en) Genetically engineered duckweed
CA2383926A1 (en) Functional genomics using zinc finger proteins
WO2002059277A3 (en) Electroactive materials for stimulation of biological activity of stem cells
AU560340B2 (en) Rennin from recombinant dna
AU2002250670A1 (en) Improved culture vessel having non-flat surfaces for growing or culturing cells, cellular aggregates, tissues and organoids and methods for using same
AU2002235994A1 (en) Method for producing proteins by fermentation of microorganisms from the thermus family, the protein mixture thus obtained and cosmetic compositions containing same
AU3462899A (en) Sequence and method for genetic engineering of proteins with cell membrane translocating activity
EP1005529A4 (en) Methods for lyophilizing competent cells
WO2003016511A1 (en) Method of extended culture for antigen-specific cytotoxic t lumphocytes
WO2004044183A3 (en) Feeding processes for fermentation
WO2000029551A3 (en) Cells, culture methods, and their use in autologous transplantation therapy
WO2000004051A3 (en) Growth differentiation factor promoter and uses therefor
WO2002002591A3 (en) Peptides for use in culture media
GB9901499D0 (en) Biological control
EP1728859A4 (en) Sequence capable of accelerating gene expression at moderately low temperature
EP2281892A3 (en) Methods for producing polypeptides in respiratory-deficient Trichoderma cells
AU2001278700A1 (en) Method of culturing human chondrocytes
AU2787400A (en) Compositions and methods for modulating growth or differentiation of growth-factor dependent cells
WO2000006713A3 (en) Methods for recombinant protein production in mammalian cells comprising co-expression with fetuin
HK1052029A1 (en) Method for increasing the yield of recombinant proteins in microbial fermentation processes.
CA2375549A1 (en) Delivery system for biological material
WO2001040443A3 (en) Method for producing adherent animal cells
WO2004096991A3 (en) Bcl2l12 polypeptide activators and inhibitors
AU2003245850A1 (en) Culture systems for the sterile continuous cultivation of cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2318402

Country of ref document: CA

Ref country code: CA

Ref document number: 2318402

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 540254

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 22132/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999902059

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09600241

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999902059

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 22132/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999902059

Country of ref document: EP